These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 35925259)

  • 1. Comparison of the efficacy between sequential therapy with teriparatide and denosumab and denosumab monotherapy in suppressing fragility fracture risk.
    Shin JW; He Q; Suk YJ; Kim SH; Kim HS
    Osteoporos Int; 2022 Nov; 33(11):2409-2416. PubMed ID: 35925259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of bone remodeling agents following teriparatide treatment.
    Burkard D; Beckett T; Kourtjian E; Messingschlager C; Sipahi R; Padley M; Stubbart J
    Osteoporos Int; 2018 Jun; 29(6):1351-1357. PubMed ID: 29541794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05.
    Mori S; Hagino H; Sugimoto T; Tanaka S; Mitomo Y; Takahashi K; Sone T; Nakamura T; Soen S
    Osteoporos Int; 2023 Jan; 34(1):189-199. PubMed ID: 36239756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to Therapy With Teriparatide, Denosumab, or Both in Postmenopausal Women in the DATA (Denosumab and Teriparatide Administration) Study Randomized Controlled Trial.
    Leder BZ; Tsai JN; Neer RM; Uihlein AV; Wallace PM; Burnett-Bowie SA
    J Clin Densitom; 2016; 19(3):346-51. PubMed ID: 26900146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months.
    Anastasilakis AD; Polyzos SA; Makras P; Gkiomisi A; Bisbinas I; Katsarou A; Filippaios A; Mantzoros CS
    Osteoporos Int; 2014 May; 25(5):1633-42. PubMed ID: 24599275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
    Leder BZ; Tsai JN; Uihlein AV; Wallace PM; Lee H; Neer RM; Burnett-Bowie SA
    Lancet; 2015 Sep; 386(9999):1147-55. PubMed ID: 26144908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Standard Versus Cyclic Teriparatide and Denosumab Treatment for Osteoporosis: A Randomized Trial.
    Cosman F; McMahon D; Dempster D; Nieves JW
    J Bone Miner Res; 2020 Feb; 35(2):219-225. PubMed ID: 31419313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of sequential therapy from short-term teriparatide to denosumab compared with denosumab alone in patients with osteoporotic hip fracture: a 1-year follow-up study.
    Park CH; Yoo JI; Choi CH; Suh YS
    BMC Musculoskelet Disord; 2020 Nov; 21(1):751. PubMed ID: 33189148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up).
    Leder BZ; Tsai JN; Jiang LA; Lee H
    Bone; 2017 May; 98():54-58. PubMed ID: 28286299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: Combined and sequential approaches.
    Langdahl B
    Bone; 2020 Oct; 139():115516. PubMed ID: 32622871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching to Denosumab or Bisphosphonates After Completion of Teriparatide Treatment in Women With Severe Postmenopausal Osteoporosis.
    Kocjan T; Rajic AS; Janez A; Vidmar G; Orehek N; Marc J; Ostanek B
    Endocr Pract; 2021 Sep; 27(9):941-947. PubMed ID: 34111556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.
    Leder BZ; Tsai JN; Uihlein AV; Burnett-Bowie SA; Zhu Y; Foley K; Lee H; Neer RM
    J Clin Endocrinol Metab; 2014 May; 99(5):1694-700. PubMed ID: 24517156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of switching from teriparatide to zoledronic acid or denosumab on bone mineral density and biochemical markers of bone turnover in older patients with severe osteoporosis: a real-life study.
    Dito G; Lugaresi M; Degradi C; Guabello G; Longhi M; Corbetta S
    Endocrine; 2023 Oct; 82(1):181-189. PubMed ID: 37402061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parathyroid Hormone and Parathyroid Hormone-Related Protein Analogs in Osteoporosis Therapy.
    Leder BZ
    Curr Osteoporos Rep; 2017 Apr; 15(2):110-119. PubMed ID: 28303448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis.
    McClung MR; Lippuner K; Brandi ML; Zanchetta JR; Bone HG; Chapurlat R; Hans D; Wang A; Zapalowski C; Libanati C
    Osteoporos Int; 2017 Oct; 28(10):2967-2973. PubMed ID: 28748386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Antiosteoporotic Medications in Patients With Rebound-Associated Fractures After Denosumab Discontinuation.
    Anastasilakis AD; Polyzos SA; Makras P; Trovas G; Yavropoulou MP; Tournis S
    J Clin Densitom; 2021; 24(4):591-596. PubMed ID: 33541775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of 4-year denosumab treatment alone or in combination with teriparatide in Japanese postmenopausal osteoporotic women.
    Suzuki T; Nakamura Y; Kato H
    Mod Rheumatol; 2019 Jul; 29(4):676-681. PubMed ID: 30217118
    [No Abstract]   [Full Text] [Related]  

  • 18. Using Osteoporosis Therapies in Combination.
    McClung MR
    Curr Osteoporos Rep; 2017 Aug; 15(4):343-352. PubMed ID: 28667435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The sequential antifracturative treatment: a meta-analysis of randomized clinical trials.
    Fassio A; Gatti D; Biffi A; Ronco R; Porcu G; Adami G; Alvaro R; Bogini R; Caputi AP; Cianferotti L; Frediani B; Gonnelli S; Iolascon G; Lenzi A; Leone S; Michieli R; Migliaccio S; Nicoletti T; Paoletta M; Pennini A; Piccirilli E; Rossini M; Brandi ML; Corrao G; Tarantino U
    Ther Adv Musculoskelet Dis; 2024; 16():1759720X241234584. PubMed ID: 38654732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Model for Assessing the Clinical and Economic Benefits of Bone-forming Agents for Reducing Fractures in Postmenopausal Women at High, Near-term Risk of Osteoporotic Fracture.
    O'Hanlon CE; Parthan A; Kruse M; Cartier S; Stollenwerk B; Jiang Y; Caloyeras JP; Crittenden DB; Barron R
    Clin Ther; 2017 Jul; 39(7):1276-1290. PubMed ID: 28629610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.